臨床検査52巻11号

2008年10月発行

特集 ホルモンの病態異常と臨床検査 各論Ⅱ　多臓器，組織におけるホルモン相互間作用

9．心血管内分泌

著者： 宮森勇¹

所属機関： ¹福井大学医学部第三内科

ページ範囲：P.1361 - P.1366

はじめに

　心臓および血管細胞がナトリウム利尿ペプチドをはじめエンドセリンなど血管作動性ホルモンを産生し，局所および血液循環を介して血管収縮性や体液平衡を制御していることが明らかとなっている．また，内分泌臓器で産生されるホルモンの中には心血管に直接作用して循環調節に関与するものもある．すなわち，ホルモンと心血管は従来考えられていた以上に深く関連していると考えられる．このような領域の進歩と発展を期してわが国でも心血管内分泌代謝学会が設立され，新規の血管作動物質の作用や診断や治療に対する応用が多数報告されている．このうち利尿ペプチド，RAS(renin-angiotensin system)系は他稿で述べられており，本稿ではステロイドホルモンと心血管について概説する．

参考文献

1) McFarlane SI, Sowers JR：Cardiovascular endocrinology 1：aldosterone function in diabetes mellitus：effects on cardiovascular and renal disease. J Clin Endocrinol Metab　88：516-523, 2003

2) Brilla CG, Weber KT, et al：Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med　120：893-901, 1992

3) Rocha R, Rudolph AE, Frierdich GE, et al：Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol　283：H1802-1810, 2002

4) Rocha R, Martin-Berger CL, Yang P, et al：Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology　143：4828-4836, 2002

5) Conlin PR：Interactions of high salt intake and the response of the cardiovascular system to aldosterone. Cardiol Rev　13：118-124, 2005

6) Miyamori I, Yoshida M, Morikawa N, et al：30th International Aldosterone Conference, New Orleans. 2004

7) Funder JW：Is aldosterone bad for the heart? Trends Endocrinol Metab　15：139-142, 2004

8) Olivieri O, Ciacciarelli A, Signorelli D, et al：Aldosterone to Renin ratio in a primary care setting：the Bussolengo study. J Clin Endocrinol Metab　89：4221-4226, 2004

9) Liu SL, Schmuck S, Chorazcyzewski JZ, et al：Aldosterone regulates vascular reactivity：short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation　108：2400-2406, 2003

10) Uhrenholt TR, Schjerning J, Hansen PB, et al：Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Cir Res　93：1258-1266, 2003

11) Arima S, Kohagura K, Xu HL, et al：Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension　43：352-357, 2004

12) Xiao F, Puddefoot JR, Barker S, et al：Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension　44：340-345, 2004

13) Ikeda U, Kanbe T, Nakayama I, et al：Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol　290：69-73, 1995

14) Callera GE, Touyz RM, Tostes RC, et al：Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension　45：773-779, 2005

15) Wehling M, Neylon CB, Fullerton M, et al：Nongenomic effects of aldosterone on intracellular Ca2＋ in vascular smooth muscle cells. Cir Res　76：973-979, 1995

16) Christ M, Meyer C, Sippel K, et al：Rapid aldosterone signaling in vascular smooth muscle cells：involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 　213：123-129, 1995

17) Alzamora R, Michea L, Marusic ET：Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension　35：1099-1104, 2000

18) Alzamora R, Marusic ET, Gonzalez M, et al：Nongenomic effect of aldosterone on Na＋, K＋-adenosine triphosphatase in arterial vessels. Endocrinology　144：1266-1272, 2003

19) Jaffe IZ, Mendelsohn ME：Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Cir Res　96：643-650, 2005

20) Brandes RP：Avoiding vicious circles：mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction. Hypertension　50：842-843, 2007

21) Sartório CL, Fraccarollo D, Galuppo P, et al：Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension　50：919-925, 2007

22) Yoshida M, Ma J, Tomita T, et al：Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail　11：12-16, 2005

23) Kuster GM, Kotlyar E, Rude MK, et al：Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation　111：420-427, 2005

24) Nishizaka MK, Zaman MA, Green SA, et al：Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation　109：2857-2861, 2004

25) Abiose AK, Mansoor GA, Barry M, et al：Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am J Cardiol　93：1564-1566, 2004

26) Williams GH, Burgess E, Kolloch RE, et al：Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol　93：990-996, 2004

27) Fan C, Kawai Y, Inaba S, et al：Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. J Steroid Biochem Mol Biol　111：29-36, 2008